期刊
CANCER CELL
卷 29, 期 4, 页码 464-476出版社
CELL PRESS
DOI: 10.1016/j.ccell.2016.03.007
关键词
-
资金
- NIH [CA176745, CA140575, CA66996, P30CA008748]
- Leukemia and Lymphoma Society
- EMBO Long-Term Fellowship [ALTF 1235-2015]
- Marie Curie Actions
- CURE Childhood Cancer Research Grant
The epigenome is a key determinant of transcriptional output. Perturbations within the epigenome are thought to be a key feature of many, perhaps all cancers, and it is now clear that epigenetic changes are instrumental in cancer development. The inherent reversibility of these changes makes them attractive targets for therapeutic manipulation, and a number of small molecules targeting chromatin-based mechanisms are currently in clinical trials. In this perspective we discuss how understanding the cancer epigenome is providing insights into disease pathogenesis and informing drug development. We also highlight additional opportunities to further unlock the therapeutic potential within the cancer epigenome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据